Accuray Incorporated (ARAY) continued its upward trend with the stock climbing 5.94% or $0.3 to close the day at $5.35 on light trading volume of 0.88M shares, compared to its three month average trading volume of 680.88K. The Sunnyvale California 94089 based company has been underperforming the medical appliances & equipment group over the past 52 weeks, with the stock losing -24.11%, compared to the industry which has advanced 8.58% over the same period. With RSI of 54.27, the stock should still continue to rise and get closer to its one year target estimate of $7.83, making it a hold for now.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
Agios Pharmaceuticals, Inc. (AGIO) grew with the stock adding 0.71% or $0.45 to close at $64.22 on light trading volume of 0.88M compared its three months average trading volume of 720.55K. The Cambridge Massachusetts 02139 based company operating under the Biotechnology industry has been trending up for the last 52 weeks, with the shares price now 0.61% up for the period and down by -1.08% so far this year. With price target of $62.71 and a 91.7% rebound from 52-week low, Agios Pharmaceuticals, Inc. has plenty of upside potential, making it a hold with a view buy.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The companys product candidates include AG-221, an potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II, Phase Ib combination, and Phase III IDHENTIFY clinical trials for the treatment of hematologic malignancies, as well as is in Phase 1/2 clinical trial for treating solid tumors, including AITL. Its product candidates also comprise AG-120, an potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical and Phase Ib combination clinical trials for the treatment of hematologic malignancies, as well as Phase I clinical trial for treating solid tumors; and AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors. In addition, the company is involved in developing AG-348, an potent activator that is in Phase II DRIVE PK clinical trial; and AG-519 potent activator that are in Phase I clinical trial for treating patients with pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; Celgene International II Sarl to develop and commercialize AG-881 products; and Abbott and Celgene Corp. to develop and commercialize companion diagnostic tests on Abbott’s m2000 RealTime System. The company was founded in 2007 and is based in Cambridge, Massachusetts.
OFG Bancorp (OFG) continued its upward trend with the stock climbing 10.57% or $1.2 to close the day at $12.55 on lower than average trading volume of 0.88M shares, compared to its three month average trading volume of 272.58K. The San Juan 00918 based company has been outperforming the money center banks companies by 17.2343% for last three months and its recent gains have pushed the stock slightly up 75.35% YTD, versus the money center banks industry which is down -10.85% for the same period. The RSI of 82.35 indicates the stock is overbought at the current levels, sell for now.
OFG Bancorp, a financial holding company, provides various banking and financial services primarily in Puerto Rico. It operates in three segments: Banking, Wealth Management, and Treasury. The Banking segment offers checking, savings, and time deposit accounts; mortgage, commercial, consumer, and auto lending products; financial planning, insurance, financial service, and investment brokerage; and corporate and individual trust and retirement services. This segment operates 48 branches in Puerto Rico. The Wealth Management segment offers securities brokerage, trust, retirement planning, insurance, pension administration, and other financial services. Its securities brokerage services cover various investment alternatives, such as tax-advantaged fixed income securities, mutual funds, stocks, and bonds to retail and institutional clients. This segment also provides separately-managed accounts and mutual fund asset allocation programs; and manages and participates in public offerings and private placements of debt and equity securities, as well as provides underwriting, merger-and-acquisition, and financial restructuring advisory services. In addition, this segment is involved in the insurance agency and administration of retirement plans in the United States, Puerto Rico, and the Caribbean. The Treasury segment is involved in various treasury-related functions with an investment portfolio consisting of mortgage-backed securities, obligations of U.S. government sponsored agencies, Puerto Rico government and agency obligations, and money market instruments. OFG Bancorp was founded in 1964 and is based in San Juan, Puerto Rico.